Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA (“GTC”) today announced a collaboration to integrate GTC’s next-generation sequencing (NGS) ...
As prevention trials for Alzheimer’s disease ramp up, researchers need fast and cheap ways to diagnose early, and to screen cognitively normal people. PET is expensive. Cerebrospinal fluid (CSF) ...
The second question, is does any additional diagnostic accuracy provided by the CSF test matter? In clinical practice, a laboratory test that confirmed Alzheimer's disease would remove ambiguity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results